BR112016030018A2 - sal composto de heterocíclico substituído com halogênio - Google Patents

sal composto de heterocíclico substituído com halogênio

Info

Publication number
BR112016030018A2
BR112016030018A2 BR112016030018A BR112016030018A BR112016030018A2 BR 112016030018 A2 BR112016030018 A2 BR 112016030018A2 BR 112016030018 A BR112016030018 A BR 112016030018A BR 112016030018 A BR112016030018 A BR 112016030018A BR 112016030018 A2 BR112016030018 A2 BR 112016030018A2
Authority
BR
Brazil
Prior art keywords
halogen substituted
substituted heterocyclic
salt
metal
heterocyclic salt
Prior art date
Application number
BR112016030018A
Other languages
English (en)
Other versions
BR112016030018A8 (pt
BR112016030018B1 (pt
Inventor
Okanari Eiji
Matsunaga Hirofumi
Nishida Hiroshi
Nishikawa Kenji
Okudo Makoto
Ito Masaaki
Matoyama Masaaki
Iwase Noriaki
Ushiyama Shigeru
Kono Shigeyuki
Kimura Tomio
Original Assignee
Ube Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ube Industries filed Critical Ube Industries
Publication of BR112016030018A2 publication Critical patent/BR112016030018A2/pt
Publication of BR112016030018A8 publication Critical patent/BR112016030018A8/pt
Publication of BR112016030018B1 publication Critical patent/BR112016030018B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

é fornecido um novo sal composto de tiofeno substituído com a-halogênio que tem uma potente ação antagonista do receptor de lpa e é útil como um produto farmacêutico. um sal representado pela fórmula geral (i): em que r é um átomo de hidrogênio ou um grupo metóxi; x é um átomo de halogênio; a é selecionado do grupo que consiste nos seguintes grupos: a; m é um metal alcalino ou um metal alcalinoterroso e n é 1 quando m é um metal alcalino e é 2 quando m é um metal alcalino-terroso].
BR112016030018-1A 2014-06-27 2015-06-26 Sal composto de heterocíclico substituído com halogênio, antagonista do receptor de lpa, composição farmacêutica e uso do referido sal BR112016030018B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014132413 2014-06-27
JP2014-132413 2014-06-27
PCT/JP2015/068575 WO2015199234A1 (ja) 2014-06-27 2015-06-26 ハロゲン置換へテロ環化合物の塩

Publications (3)

Publication Number Publication Date
BR112016030018A2 true BR112016030018A2 (pt) 2017-08-22
BR112016030018A8 BR112016030018A8 (pt) 2023-05-09
BR112016030018B1 BR112016030018B1 (pt) 2023-07-04

Family

ID=

Also Published As

Publication number Publication date
AU2015281021B9 (en) 2019-03-28
MX370408B (es) 2019-12-11
US10023554B2 (en) 2018-07-17
EP3162801A1 (en) 2017-05-03
CN106458964B (zh) 2019-11-22
EP3162801B1 (en) 2020-07-22
RU2689315C2 (ru) 2019-05-27
WO2015199234A1 (ja) 2015-12-30
AU2015281021B2 (en) 2019-03-14
KR20170016988A (ko) 2017-02-14
AU2015281021A1 (en) 2017-01-19
JP6579103B2 (ja) 2019-09-25
MX2016017371A (es) 2017-05-01
JPWO2015199234A1 (ja) 2017-04-27
ES2824801T3 (es) 2021-05-13
BR112016030018A8 (pt) 2023-05-09
CA2953472A1 (en) 2015-12-30
CA2953472C (en) 2022-08-02
RU2017102513A3 (pt) 2018-12-11
KR102433588B1 (ko) 2022-08-19
US20170158663A1 (en) 2017-06-08
EP3162801A4 (en) 2018-01-24
RU2017102513A (ru) 2018-07-27
CN106458964A (zh) 2017-02-22

Similar Documents

Publication Publication Date Title
BR112017006240A2 (pt) novos compostos
MX2020005873A (es) Compuestos de 6-azaindol.
MX2016011992A (es) Derivados de piperidina-diona.
CL2016000581A1 (es) Pesticidas de azol bicíclicos sustituidos por heterociclo.
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
MX2020006168A (es) Compuestos de 4-azaindol.
CR20150509A (es) Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
MX2015010775A (es) Benzoxazoles sustituidos y metodos para usarlos.
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
MX2016017371A (es) Sal de compuesto heterociclico sustituido con halogeno.
UY34833A (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano RORy
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
MX2015011436A (es) Triazolopiridinas sustituidas y metodos para usarlas.
GEP20196942B (en) Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors
MX2020006014A (es) Compuestos de diazaindol.
RS54730B1 (sr) Inhibitori beta sekretaze
MA39956A (fr) Analogues du benzomorphane et leur utilisation
BR112016001979A2 (pt) composto de tetrazolinona e uso do mesmo
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
AR090596A1 (es) Formulaciones farmaceuticas que comprenden antagonistas de ccr3
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
AR103317A1 (es) Moduladores de ciclopropil dihidrobenzofurano de receptores de melatonina
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
JOP20200030A1 (ar) مركب خماسي الحلقة

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UBE CORPORATION (JP)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/06/2015, OBSERVADAS AS CONDICOES LEGAIS